Entries by Info

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

– Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study – Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America   Utrecht, The Netherlands, 12 November 2020 – AM-Pharma B.V., an emerging leader focused on the […]

AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team

Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development. Dr. Meder, who brings nearly 20 years of […]